Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 10, Issue SUPPL. 1, 1996, Pages 19-21

  Gauthier, S ^a   Montplaisir, J ^b   Petit, D ^b   Joanette, Y ^c   Feldman, H ^d   Mohr, E ^e   Nair, N P V ^f   Poirier, J ^a,f  

^a MCGILL UNIVERSITY   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c Lab Théophile Alajouanine   (Canada)

^d VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^e ROYAL OTTAWA HOSPITAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; ESTROGEN; LAZABEMIDE; MONOAMINE OXIDASE B INHIBITOR; PREDNISONE; SELEGILINE;

ALZHEIMER DISEASE; CLINICAL PROTOCOL; COGNITIVE DEFECT; DIAGNOSTIC PROCEDURE; HIGH RISK POPULATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

EID: 0029792157     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199601031-00006     Document Type: Short Survey

References (11)

1. Berg L, Danziger WL, Storandt M, et al. Predictive features in mild senile dementia of the Alzheimer type. Neurology 1984;34:563-9.
2. Feldman H, Schulzer M, Wang S, et al. The Functional Rating Scale (FRS) in Alzheimer's disease: a longitudinal study. In: Iqbal K, Mortimer J, Winblad B, Wisienwski H, eds. Recent advances in Alzheimer's disease and related disorders. London: Wiley, 1995:235-41.
3. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995;45:1451-5.
4. Gauthier L, Gauthier S. Assessment of functional changes in Alzheimer's disease. Neuroepidemiology 1990;9:183-8.
5. Gauthier L, Gauthier S, Gélinas I, McIntyre M, Wood-Dauphinee S. Assessment of functioning and ADL. Abstract book of the Sixth Congress of the International Psychogeriatric Association, 1993:9.
6. Joanette Y, Ska B, Poissant A, Béland R. Neuropsychological aspects of Alzheimer's disease: evidence for inter- and intra-function heterogeneity. In: Boiler F, Forette F, Khachaturian Z, Poncet M, Christen Y, eds. Heterogeneity of Alzheimer's disease. Montreal: Springer-Verlag, 1992:33-42.
7. Lupien S, Lecours AR, Schwartz G, Sharma S, Nair NPV, Meaney MJ. Neuropsychological assessment of healthy elderly subjects in relation to basal cortisol activity. J Neurosci 1994;14:2893-903.
8. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive changes in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993;43:2457-65.
9. Nalbantoglu J, Gilfix BM, Bertrand P, et al. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol 1994;36:889-95.
10. Petit D, Montplaisir J, Lorrain D, Gauthier S. Spectral analysis of the rapid eye movement sleep electroencephalogram in right and left temporal regions: a biological marker of Alzheimer's disease. Ann Neurol 1992;32:172-6.
11. Valdois S, Joanette Y, Poissant A, Ska B, Dehaut F. Heterogeneity in the Cognitive Profile of Normal Elderly. J Clin Exp Neuropsychol 1990;12:587-96.